Rallybio CMO Departs Amid Pending Candid Therapeutics Merger

Rallybio ( (RLYB) ) has issued an announcement.

On March 31, 2026, Rallybio Corporation announced that Chief Medical Officer Steven Ryder, M.D., who has served in that role since January 2019, has left the company effective immediately. His departure comes as Rallybio prepares for a pending business combination with Candid Therapeutics, Inc. under a merger agreement signed on March 1, 2026.

Under a separation agreement, Dr. Ryder will receive severance payments and benefits consistent with a termination without cause under his existing employment contract. Following the closing of the merger, he is also entitled to additional change-of-control severance, offset by the initial amounts already paid to him.

Ryder’s restricted stock, stock options and other equity awards will remain outstanding and eligible to vest in line with the merger terms, and will be exercisable for up to 90 days after the transaction closes. The move signals executive transition at Rallybio during a critical M&A process, with compensation and equity treatment structured to bridge leadership changes through the completion of the deal.

The most recent analyst rating on (RLYB) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Rallybio stock, see the RLYB Stock Forecast page.

Spark’s Take on RLYB Stock

According to Spark, TipRanks’ AI Analyst, RLYB is a Neutral.

The score is driven by strong technical momentum and a highly positive corporate catalyst (merger plus large financing). These are partially offset by weak underlying financial performance, including ongoing losses and significant cash burn despite low leverage.

To see Spark’s full report on RLYB stock, click here.

More about Rallybio

Rallybio Corporation is a biopharmaceutical company focused on developing therapies in collaboration with partners such as Candid Therapeutics, Inc. The company is currently pursuing a business combination with Candid under an Agreement and Plan of Merger and Reorganization signed on March 1, 2026.

Rallybio operates within a sector where leadership continuity and executive incentives are closely tied to major transactions. Its pending merger underscores a strategic emphasis on corporate combinations and change-of-control structures that can reshape management and equity arrangements for key executives.

The company’s equity awards, including restricted stock and stock options, play an important role in retaining and rewarding senior leadership. These instruments are structured to remain in place and potentially vest through significant corporate events, such as the closing of the proposed merger with Candid.

Average Trading Volume: 134,887

Technical Sentiment Signal: Buy

Current Market Cap: $42.53M

For a thorough assessment of RLYB stock, go to TipRanks’ Stock Analysis page.